Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01278225 · ClinicalTrials.gov registry record

Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain

A clinical trial of Pain and Peripheral Neuropathy, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
80
Enrollment target
1
Study location

NCT01278225: Active study of Pain and Peripheral Neuropathy, sponsored by M.D. Anderson Cancer Center.

NCT01278225 is a study of Pain and Peripheral Neuropathy that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01278225, a study of Pain and Peripheral Neuropathy, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to learn if using a non-invasive therapy called "neurofeedback training" can help teach patients ways to modify their own brain waves to decrease the perception of pain and improve quality of life.

Primary Outcome

After Group 1 has completed neurofeedback training, both Groups will fill out the same 10 questionnaires that were completed at baseline. An EEG will be performed on both Groups about 1 week after Group 1 completes last neurofeedback training, and again 4 months later.

Interventions

  • BEHAVIORAL EEG biofeedback (BF) Group
  • BEHAVIORAL Wait-List Control (WLC) Group
  • BEHAVIORAL Follow UP Questionnaires

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2011-02
Est. Completion 2027-04-01
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT01278225 still lists

NCT01278225 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (74% lower).

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 3 interventions - of which EEG biofeedback (BF) Group is the first listed.

NCT01278225 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01278225 about?

NCT01278225 is a clinical study titled "Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain". The goal of this study is to learn if using a non-invasive therapy called "neurofeedback training" can help teach patients ways to modify their own brain waves to decrease the perception of pain and improve quality of life.

What is the current status of trial NCT01278225?

This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2011-02. Estimated completion is 2027-04-01.

What conditions does trial NCT01278225 study?

This clinical trial studies the following conditions: Pain, Peripheral Neuropathy.

What interventions are being tested in trial NCT01278225?

The interventions under investigation include: EEG biofeedback (BF) Group (BEHAVIORAL), Wait-List Control (WLC) Group (BEHAVIORAL), Follow UP Questionnaires (BEHAVIORAL).

Who is sponsoring clinical trial NCT01278225?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01278225 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01278225's enrollment target sits among peer trials

80 193rd of 374 higher than 171 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01278225, the US trial registry maintained by the National Library of Medicine. NCT01278225 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.